Table 3.

Phase II studies of eribulin in patients with metastatic breast cancer who have previously received an anthracycline and taxane

n	201 [27]	211 [28]	221 [29]
	87 (per protocol population)	269 (eligible population)	80 (eligible population)
Prior chemotherapy	Any prior regimen of chemotherapy with A and T (median 4)	2–5 prior regimens of chemotherapy with A, T and CAP (median 4)	≤3 prior regimens of chemotherapy including A and T (median 3)
Dosing schedule	1.4 mg/m2 IV inf d1 + 8 + 15 q4w 1.4 mg/m2 IV inf d1 + 8 q3w	1.4 mg/m2 IV inf d1 + 8 q3w	1.4 mg/m2 IV inf d1 + 8 q3w
Tumour response (independent review)
PR (%)	11.5 [total]	9.3	21.3
	10.2 [q4w cohort]
	14.3 [q3w cohort]
SD (%)	42.5 [total]	46.5	37.5
	35.6 [q4w cohort]
	57.1 [q3w cohort]
ORRa (%)	11.5 [total]	9.3	21.3
	10.2 [q4w cohort]
	14.3 [q3w cohort]
CBRb (%)	17.2 [total]	17.1	27.5
	11.9 [q4w cohort]
	28.6 [q3w cohort]
Median duration of response (months)	5.6	4.1	3.9
Median PFS (months)	2.6	2.6	3.7
Median OS (months)	9.0	10.4	11.1

A anthracycline, CAP capecitabine, CBR clinical benefit rate, d day, IV inf intravenous infusion, ORR objective response rate, OS overall survival, PFS progression-free survival, PR partial response, qXw every X weeks, SD stable disease, T taxane

^aObjective response rate = complete response + partial response

^bClinical benefit rate = complete response + partial response + stable disease ≥6 months